ATX-101 is under clinical development by APIM Therapeutics and currently in Phase II for Liposarcoma. According to GlobalData, Phase II drugs for Liposarcoma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ATX-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ATX-101 overview

ATX-101 is under development for the treatment of blood cancer and solid tumors such as ovarian cancer, fallopian tube cancer, peritoneal cancer, non-muscle invasive bladder cancer, breast cancer, advanced bladder cancer, multiple myeloma, prostate cancer, glioblastoma, advanced malignancy, acute myeloid leukemia, leiomyosarcoma and liposarcoma. The drug candidate is administered by intravesical and intravenous routes. It is a short-chained peptide compound engineered to penetrate cells, enters the nucleus and target PCNA (Proliferating Cell Nuclear Antigen). It comprises of Proliferating Cell Nuclear Antigen (PCNA) interacting stress switch peptide motif termed APIM.

APIM Therapeutics overview

APIM Therapeutics (APIM) is a biotechnology company that develops novel anti-cancer agents targeting stress responses. The company offers peptide compounds such as mitomycin-c, cisplatin, melphatan, ATX compounds, cytarabine, cisplatin, docetaxel and temozolomide. Its compounds are used in indication of superficial bladder cancer, advanced bladder cancer, multiple myeloma, acute myeloid, prostate cancer and gliobastoma. The company offers research and development, proof of concept studies, preclinical studies; CTA and phase development programs. It offers novel PCNA-interacting peptides, which provide novel intervention point allowing cancer-specific tumor cell elimination. APIM is headquartered in Trondheim, Norway.

For a complete picture of ATX-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.